RT Journal Article
T1 Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study.
A1 Hernández, Domingo
A1 Ruiz-Esteban, Pedro
A1 Gaitán, Daniel
A1 Burgos, Dolores
A1 Mazuecos, Auxiliadora
A1 Collantes, Rocío
A1 Briceño, Eva
A1 Palma, Eulalia
A1 Cabello, Mercedes
A1 González-Molina, Miguel
A1 De Mora, Manuel
K1 Everolimus
K1 Left ventricular hupertrophy
K1 Renin-angiotensis blockers
K1 Sirolimus
K1 Kidney transplantation
AB BACKGROUNDLeft ventricular hypertrophy (LVH) is common in kidney transplant (KT) recipients. LVH is associated with a worse outcome, though m-TOR therapy may help to revert this complication. We therefore conducted a longitudinal study to assess morphological and functional echocardiographic changes after conversion from CNI to m-TOR inhibitor drugs in nondiabetic KT patients who had previously received RAS blockers during the follow-up.METHODSWe undertook a 1-year nonrandomized controlled study in 30 non-diabetic KT patients who were converted from calcineurin inhibitor (CNI) to m-TOR therapy. A control group received immunosuppressive therapy based on CNIs. Two echocardiograms were done during the follow-up.RESULTSNineteen patients were switched to SRL and 11 to EVL. The m-TOR group showed a significant reduction in LVMi after 1 year (from 62 ± 22 to 55 ± 20 g/m2.7; P=0.003, paired t-test). A higher proportion of patients showing LVMi reduction was observed in the m-TOR group (53.3 versus 29.3%, P=0.048) at the study end. In addition, only 56% of the m-TOR patients had LVH at the study end compared to 77% of the control group (P=0.047). A significant change from baseline in deceleration time in early diastole was observed in the m-TOR group compared with the control group (P=0.019).CONCLUSIONSSwitching from CNI to m-TOR therapy in non-diabetic KT patients may regress LVH, independently of blood pressure changes and follow-up time. This suggests a direct non-hemodynamic effect of m-TOR drugs on cardiac mass.
PB BioMed Central
YR 2014
FD 2014-04-23
LK http://hdl.handle.net/10668/2043
UL http://hdl.handle.net/10668/2043
LA en
NO Hernández D, Ruiz-Esteban P, Gaitán D, Burgos D, Mazuecos A, Collantes R, et al. Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study. BMC Nephrol. 2014; 15:65
NO Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;
DS RISalud
RD Nov 6, 2025